Logo

AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

Share this

AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

Shots:

  • Theragonistics to get intellectual property rights to operate globally in the diagnostic field for selected radio radionuclide labeled PARPi along with an exclusive option to license for operating globally in the therapeutic field of selected rPARPi
  • Theragonistics will develop molecular radiotherapy based on PARP inhibitor through its platform for the diagnosis and treatment of multiple cancer
  • PARP inhibitors are a novel class of cancer therapies act by inhibiting Poly (ADP-Ribose) Polymerase enzyme which is used by cancerous cells to damage DNA both endogenous and as caused by treatments like chemotherapy

Click here to­ read full press release/ article

Ref: PRNewswire | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions